Determination of ESR1 mutations
PreclinicalBiologic
Determination of ESR1 mutations is one of 80 biologic programs targeting Breast Cancer. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Tianeptine
PfizerPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Bisphosphonate
AmgenPreclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- CCentre Henri Becquerel